Mechanisms of genistein protection on pancreas cell damage in high glucose condition

Related Experiment Video

Updated: May 28, 2026

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

Wen-Wen Zhong1, Yang Liu, Chun-Lin Li

  • 1Department of Geriatric Endocrinology, The Chinese PLA General Hospital, China.

Internal Medicine (Tokyo, Japan)
|October 4, 2011
PubMed
Abstract

Insights

Phytoestrogen genistein protects human pancreatic cells from high glucose damage. This effect is mediated through estrogen receptor beta and Bcl-2 pathways, offering potential for type 2 diabetes prevention.

Area of Science:

  • Endocrinology
  • Cell Biology
  • Molecular Biology

Background:

  • Type 2 diabetes is linked to inadequate pancreatic beta cell numbers.
  • High glucose levels induce apoptosis in pancreatic beta cells, contributing to diabetes development.

Purpose of the Study:

  • To investigate the protective effects of genistein, a phytoestrogen, against high glucose-induced apoptosis in human pancreatic beta cells.
  • To elucidate the underlying mechanisms, including the roles of estrogen receptor beta and Bcl-2.

Main Methods:

  • Human pancreatic beta cells were exposed to normal or high glucose conditions with/without genistein.
  • The impact of ICI-182780 (anti-estrogen) and Bcl-2 siRNA was assessed.
  • Cell proliferation, apoptosis, and gene expression (estrogen receptor, Bcl-2) were measured.

Main Results:

  • High glucose significantly inhibited proliferation and induced apoptosis in beta cells.
  • Genistein treatment reversed these detrimental effects.
  • Genistein's protective action was blocked by ICI-182780 and Bcl-2 siRNA, indicating involvement of these pathways.

Conclusions:

  • Genistein demonstrates protective effects against high glucose-induced pancreatic beta cell damage.
  • These protective mechanisms involve estrogen receptor beta and Bcl-2 signaling pathways.
  • Genistein may represent a therapeutic strategy for managing type 2 diabetes.

More Related Videos

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

Related Concept Videos

Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...